Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 233,155,040
  • Shares Outstanding, K 6,833,384
  • Annual Sales, $ 58,120 M
  • Annual Income, $ 10,735 M
  • 60-Month Beta 0.52
  • Price/Sales 4.01
  • Price/Cash Flow 13.42
  • Price/Book 7.61
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/31/19
  • Annual Dividend & Yield 0.68 (1.99%)
  • Most Recent Dividend 0.678 on 03/07/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.1000 +1.99%
on 03/08/19
34.9800 -3.49%
on 02/28/19
-0.9700 (-2.79%)
since 02/22/19
3-Month
29.4500 +14.63%
on 12/27/18
34.9800 -3.49%
on 02/28/19
+3.5600 (+11.79%)
since 12/21/18
52-Week
26.3000 +28.37%
on 06/08/18
34.9800 -3.49%
on 02/28/19
+5.4200 (+19.12%)
since 03/22/18

Most Recent Stories

More News
Biogen Stock Crashes on Termination of Alzheimer's Studies

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

NVS : 93.42 (-0.26%)
RHHBY : 33.7600 (-1.06%)
SNY : 44.26 (-2.58%)
BIIB : 216.71 (-4.48%)
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.

CELG : 88.15 (-1.65%)
MRK : 82.29 (-0.80%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

JNJ : 136.91 (-0.86%)
ABBV : 79.76 (-1.82%)
TEVA : 16.33 (-4.39%)
RHHBY : 33.7600 (-1.06%)
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

TRVN : 1.70 (+1.19%)
CELG : 88.15 (-1.65%)
PBYI : 39.03 (-3.37%)
RHHBY : 33.7600 (-1.06%)
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

AZN : 42.59 (-0.84%)
MRK : 82.29 (-0.80%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)
Alnylam's (ALNY) Impressive Pipeline Drives Share Price

Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

MDCO : 26.58 (-5.14%)
ALNY : 84.52 (-6.85%)
NVS : 93.42 (-0.26%)
RHHBY : 33.7600 (-1.06%)
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

AZN : 42.59 (-0.84%)
INO : 3.62 (-2.69%)
RHHBY : 33.7600 (-1.06%)
REGN : 391.80 (-2.68%)
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

JNJ : 136.91 (-0.86%)
MRK : 82.29 (-0.80%)
AGN : 149.30 (-2.76%)
RHHBY : 33.7600 (-1.06%)
PFE : 41.85 (-1.18%)
Roche Gets Approval for Label Expansion of MabThera in Europe

Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

CELG : 88.15 (-1.65%)
NVS : 93.42 (-0.26%)
RHHBY : 33.7600 (-1.06%)
AMGN : 186.70 (-2.70%)
Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

RCUS : 11.19 (-5.65%)
INFI : 1.76 (+2.33%)
RHHBY : 33.7600 (-1.06%)
BMY : 48.16 (-1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 34.0616
1st Resistance Point 33.9108
Last Price 33.7600
1st Support Level 33.6396
2nd Support Level 33.5192

See More

52-Week High 34.9800
Last Price 33.7600
Fibonacci 61.8% 31.6642
Fibonacci 50% 30.6400
Fibonacci 38.2% 29.6158
52-Week Low 26.3000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar